As CKD progresses, the elevation of serum fibroblast growth factor 23 (FGF23) leads to suppression calcitriol production, consequently inducing hypocalcaemia and stimulating parathyroid hormone (PTH) secretion, ultimately resulting in decreased bone mineral density (BMD) [2]. This evidence concerns the gene FGF23 and chronic kidney disease.